According to a press release from Excision Biotherapeutics, a biotech company, America’s Food and Drug Administration (FDA) approved the treatment’s progression to Phase I/II human trials.
Excision’s potential cure is known as EBT-101 and is being developed in partnership with researchers from Temple University in Philadelphia.
EBT-101 cuts numerous pieces of the HIV genome in a bid to make it unable to mutate inside the body. Speaking to Fierce Biotech, Excision’s CEO Daniel Dornbusch said: “If you just make a single cut, the virus can mutate around it.
We make multiple cuts to deactivate the viral genome.” The Nobel Prize-winning CRISPR gene-editing technology is at the core of a lot of the company’s work and allows for the modification